Trending NewsTrending NewsNASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis $68.67 +5.13 (+8.07%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$68.42 -0.25 (-0.36%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GeneDx Stock (NASDAQ:WGS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GeneDx alerts:Sign Up Key Stats Today's Range$63.50▼$68.9550-Day Range$34.51▼$69.8352-Week Range$32.21▼$170.87Volume1.19 million shsAverage Volume1.11 million shsMarket Capitalization$2.04 billionP/E RatioN/ADividend YieldN/APrice Target$86.86Consensus RatingModerate Buy Company Overview GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting. Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care. In 2015, the company became a subsidiary of OPKO Health, leveraging OPKO’s global infrastructure to expand its testing capabilities and research collaborations. GeneDx holds College of American Pathologists (CAP) accreditation and is CLIA-certified, ensuring adherence to stringent quality and regulatory standards. GeneDx serves a diverse client base that includes hospitals, academic medical centers, reference laboratories and pharmaceutical partners, as well as patients participating in research studies. While its primary market is the United States, the company also accommodates international referrals through its global network, enabling access to advanced genetic diagnostics for clinicians and patients worldwide. With a dedicated team of geneticists, laboratory scientists and genetic counselors, GeneDx continues to advance precision medicine by translating complex genomic data into actionable clinical insights.AI Generated. May Contain Errors. Read More GeneDx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreWGS MarketRank™: GeneDx scored higher than 83% of companies evaluated by MarketBeat, and ranked 40th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialGeneDx has a consensus price target of $86.86, representing about 26.5% upside from its current price of $68.67.Amount of Analyst CoverageGeneDx has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GeneDx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GeneDx are expected to grow in the coming year, from ($1.00) to $0.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is -25.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is -25.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 6.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeneDx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.05% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 4.93.Change versus previous monthShort interest in GeneDx has recently increased by 31.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.17 News SentimentGeneDx has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for GeneDx this week, compared to 9 articles on an average week.Search InterestOnly 10 people have searched for WGS on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows4 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of GeneDx in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $88,883,936.00 in company stock, which represents 4.3596% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have bought 2,086.28% more of their company's stock than they have sold. Specifically, they have bought $93,144,340.00 in company stock and sold $4,260,404.00 in company stock.Percentage Held by Insiders25.17% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WGS Stock News HeadlinesGeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Deadline in Securities Fraud Class Action LawsuitJune 25 at 1:10 PM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines - WGSJune 25 at 10:00 AM | prnewswire.com2,000 missiles didn't hit Iran. They hit China.Iran sold 90% of its oil to China. Venezuela secretly shipped 80% of its exports to the same buyer. Within 60 days, America cut both supply lines - starving China's AI power grid of the cheap, endless fuel it needs to compete. Now all that energy flows through a single American chokepoint: one company, 140,000 miles of steel, and no competition. Dylan Jovine has identified the stock at the center of this strategy, along with three ascending price targets.June 26 at 1:00 AM | Behind the Markets (Ad)INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that GeneDx Holdings Corp. (WGS) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 25 at 9:00 AM | globenewswire.comGeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 3,729 Shares of StockJune 19, 2026 | insidertrades.comKevin Feeley Sells 1,266 Shares of GeneDx (NASDAQ:WGS) StockJune 12, 2026 | insidertrades.comCasdin Capital, Llc Purchases 50,000 Shares of GeneDx (NASDAQ:WGS) StockJune 9, 2026 | insidertrades.comFrom Industry Titans to Tiny Fish: 3 Key Stocks Insiders are Trading (WGS)Check out these three stocks that insiders are buying and selling, including giants in oil and AI, as well as a small gene stock seeing huge swings.June 6, 2026 | marketbeat.comSee More Headlines WGS Stock Analysis - Frequently Asked Questions How have WGS shares performed this year? GeneDx's stock was trading at $130.06 at the beginning of 2026. Since then, WGS shares have decreased by 47.2% and is now trading at $68.67. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) posted its quarterly earnings data on Monday, May, 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.22. The firm had revenue of $102.25 million for the quarter, compared to analysts' expectations of $112.46 million. GeneDx had a positive trailing twelve-month return on equity of 9.15% and a negative net margin of 17.58%. Read the conference call transcript. When did GeneDx's stock split? GeneDx shares reverse split before market open on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GeneDx's major shareholders? GeneDx's top institutional investors include Amova Asset Management Americas Inc. (2.18%), Sumitomo Mitsui Trust Group Inc. (2.16%), Bank of New York Mellon Corp (1.08%) and Dimensional Fund Advisors LP (0.91%). Insiders that own company stock include Keith A Meister, Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Katherine Stueland, Kevin Feeley, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Joshua Ruch, Jason Ryan, Karen Ann White and Bryan Dechairo. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeneDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings5/04/2026Today6/26/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 11 days, WGS's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:WGS CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,300Year Founded2000Price Target and Rating Average Price Target for GeneDx$86.86 High Price Target$150.00 Low Price Target$63.00 Potential Upside/Downside+26.5%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.02 million Net Margins-17.58% Pretax Margin-17.50% Return on Equity9.15% Return on Assets5.21% Debt Debt-to-Equity Ratio0.38 Current Ratio3.09 Quick Ratio2.95 Sales & Book Value Annual Sales$427.54 million Price / Sales4.77 Cash Flow$2.48 per share Price / Cash Flow27.72 Book Value$10.54 per share Price / Book6.52Miscellaneous Outstanding Shares29,690,000Free Float22,216,000Market Cap$2.04 billion OptionableOptionable Beta1.96 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:WGS) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our PartnersSpaceX IPO “cancelled”?SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...InvestorPlace | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe EPA just put a kill switch on Elon’s empireA federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...Behind the Markets | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredMillionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...Brownstone Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
